Evaluation of mass drug administration for schistosomiasis and soil-transmitted helminths in school-aged children in Bankass, Mali

Sangare, Moussa; Berthe, Adama; Dolo, Housseini; Diabaté, Abdoul Fatao; Konipo, Fatoumata dite Nènè; Soumaoro, Lamine; Doumbia, S.; Coulibaly, Michel Emmanuel; Diarra, Lamine; Sanogo, Yacouba; Atsou, Kueshivi Midodji; Diallo, Abdallah A.; Coulibaly, Souleymane; Keita, Modibo; Doumbia, Seydou; Coulibaly, Yaya Ibrahim

doi:10.1016/j.ijid.2021.08.063

Cited by 2 publications

(2 citation statements)

References 31 publications

(30 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Reasons attributed to non-participation were non-visitation of community volunteers, absenteeism of household members during MDA and not having enough information about the medicines. These reasons were frequently reported during the pandemic years and are consistent with other existing reports from India [ 19 ], Kenya [ 20 ], Ethiopia [ 21 ], Liberia [ 22 ] and Mali [ 23 ]. It is therefore important to reflect on these gaps and identify factors that might contribute to non-visitation of community volunteers and absenteeism of household members especially during the post-COVID lockdown era [ 11 ].…”

Section: Discussionsupporting

confidence: 91%

A Post-Lockdown Assessment of Albendazole Treatment Coverage in Mass Drug Administration Campaigns Implemented Before and During COVID-19 Pandemic in Ekiti, Southwest Nigeria

Mogaji

Okoh

Lawal³

et al. 2023

Int J Public Health

View full text Add to dashboard Cite

Objective: This study assessed the coverage of albendazole (ALB) in mass drug administration (MDA) programs implemented before (2019) and during the (2020 and 2021) COVID-19 pandemic in Ekiti State, Nigeria.Methods: Standardized questionnaires were administered to 1,127 children across three peri-urban communities to ascertain if they received and swallowed ALB across the years. Reasons, why ALB was not received, were documented and analyzed in SPSS. 20.0.Results: In 2019, the medicine reach was between 42.2%–57.8%, however, during the pandemic, the reach significantly reduced to 12.3%–18.6%, and increased to 28.5%–35.2% in 2021 (p < 0.000). About 19.6%–27.2% of the participants have missed 1 MDA, while 26.9%–37.8% and 22.4%–32.8% have missed 2 and 3 MDAs, respectively. The majority who did not receive ALB (60.8%–75%) claimed drug distributors never came, while about 14.9%–20.3% mentioned they did not hear about MDA. However, individual compliance towards swallowing was above 94% across the study years (p < 0.00).Conclusion: These results highlight the need to explore the perceptions of those who have consistently missed MDAs, and also understand the health-system-related issues including those imposed by the pandemic affecting MDA.

show abstract

Section: Discussionsupporting

confidence: 91%

A Post-Lockdown Assessment of Albendazole Treatment Coverage in Mass Drug Administration Campaigns Implemented Before and During COVID-19 Pandemic in Ekiti, Southwest Nigeria

Mogaji

Okoh

Lawal³

et al. 2023

Int J Public Health

View full text Add to dashboard Cite

show abstract

“…As a consequence, the introduction of praziquantel led to the global schistosomiasis control strategy shifting from disease control to morbidity control [26]. Mass drug administration (MDA) with praziquantel has been shown to be effective in reducing the prevalence and morbidity due to schistosomiasis [27][28][29]. Furthermore, an antifibrotic activity of praziquantel was reported in both animal models and patients infected with schistosomiasis [30,31].…”

Section: Introductionmentioning

confidence: 99%

The Role of Praziquantel in the Prevention and Treatment of Fibrosis Associated with Schistosomiasis: A Review

Niu

et al. 2022

Journal of Tropical Medicine

View full text Add to dashboard Cite

Schistosomiasis remains a major global public health concern. Currently, the control of this neglected tropical disease still depends on chemotherapy to reduce the prevalence and intensity of the parasite infection. It has been widely accepted that praziquantel is highly effective against all species of Schistosoma, and this agent is virtually the only drug of choice for the treatment of human schistosomiasis. Mass drug administration (MDA) with praziquantel has been shown to be effective in greatly reducing the prevalence and morbidity due to schistosomiasis worldwide. In addition to antischistosomal activity, a large number of experiential and clinical evidence has demonstrated the action of praziquantel against fibrosis caused by S. mansoni and S. japonicum infections through decreasing the expression of fibrotic biomarkers such as α-smooth muscle actin (α-SMA), collagen, matrix metalloproteinase (MMP), and tissue inhibitor of metalloproteinase (TIMP), and inhibiting the expression of proinflammatory cytokines such as interleukin (IL)-6, tumor necrosis factor (TNF)-α, and transforming growth factor (TGF)-β, as well as chemokines, and similar antifibrotic activity was observed in mouse models of fibrosis induced by carbon tetrachloride (CCl4) and concanavalin A (Con-A). In this review, we discuss the role of praziquantel in the prevention and treatment of fibrosis associated with schistosomiasis and the possible mechanisms. We call for randomized, controlled clinical trials to evaluate the efficacy and safety of praziquantel in the treatment of schistosomiasis-induced hepatic fibrosis, and further studies to investigate the potential of praziquantel against fibrosis associated with alcohol consumption, viruses, and toxins seem justified.

show abstract

Evaluation of mass drug administration for schistosomiasis and soil-transmitted helminths in school-aged children in Bankass, Mali

Cited by 2 publications

References 31 publications

A Post-Lockdown Assessment of Albendazole Treatment Coverage in Mass Drug Administration Campaigns Implemented Before and During COVID-19 Pandemic in Ekiti, Southwest Nigeria

A Post-Lockdown Assessment of Albendazole Treatment Coverage in Mass Drug Administration Campaigns Implemented Before and During COVID-19 Pandemic in Ekiti, Southwest Nigeria

The Role of Praziquantel in the Prevention and Treatment of Fibrosis Associated with Schistosomiasis: A Review

Contact Info

Product

Resources

About